Matches in DBpedia 2016-04 for { ?s ?p "Santaris Pharma A/S is a biopharmaceutical company founded in 2003 in Copenhagen, Denmark with a small branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris Pharma A/S has become a leading clinical-stage biopharmaceutical company that develops RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.The company was acquired by Roche in August 2014.Santaris has the worldwide exclusive intellectual property rights to the therapeutic applications of locked nucleic acid (LNA) technology. This includes ownership of over 60 patent types, which range from the chemistry to manufacturing and from therapeutic uses to drug design.With their LNA technology, Santaris works on developing drugs for a wide range of diseases using microRNA and mRNA. Their research focuses on infectious disease and metabolic disorders. They also work on collaborations with pharmaceuticals to develop drugs for rare genetic disorders, cancers, cardiovascular disease, and immune and inflammatory diseases."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Santaris_Pharma abstract "Santaris Pharma A/S is a biopharmaceutical company founded in 2003 in Copenhagen, Denmark with a small branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris Pharma A/S has become a leading clinical-stage biopharmaceutical company that develops RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.The company was acquired by Roche in August 2014.Santaris has the worldwide exclusive intellectual property rights to the therapeutic applications of locked nucleic acid (LNA) technology. This includes ownership of over 60 patent types, which range from the chemistry to manufacturing and from therapeutic uses to drug design.With their LNA technology, Santaris works on developing drugs for a wide range of diseases using microRNA and mRNA. Their research focuses on infectious disease and metabolic disorders. They also work on collaborations with pharmaceuticals to develop drugs for rare genetic disorders, cancers, cardiovascular disease, and immune and inflammatory diseases.".
- Q7420079 abstract "Santaris Pharma A/S is a biopharmaceutical company founded in 2003 in Copenhagen, Denmark with a small branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris Pharma A/S has become a leading clinical-stage biopharmaceutical company that develops RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.The company was acquired by Roche in August 2014.Santaris has the worldwide exclusive intellectual property rights to the therapeutic applications of locked nucleic acid (LNA) technology. This includes ownership of over 60 patent types, which range from the chemistry to manufacturing and from therapeutic uses to drug design.With their LNA technology, Santaris works on developing drugs for a wide range of diseases using microRNA and mRNA. Their research focuses on infectious disease and metabolic disorders. They also work on collaborations with pharmaceuticals to develop drugs for rare genetic disorders, cancers, cardiovascular disease, and immune and inflammatory diseases.".